{
  "drug_name": "Cephalexin",
  "tradename": "Keflex, Keftab",
  "usage_and_dosing": {
    "general": [
      "Cephalexin, FDA-approved in 1971, is a 1st generation oral cephalosporin with in vitro activity against streptococci, MSSA, E. coli, Klebsiella sp., and P. mirabilis.",
      "Can cause false-negative urine dipstick test for leukocytes (Am Fam Phys 2005;71:1153)."
    ],
    "adult_dose": {
      "usual_dose": "250-1000 mg po q6h (max 4 gm/day)"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "25-100 mg/kg/day (divided q6h)",
      "max_day": "4 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "0.5-1.2",
    "half_life_esrd": "5-30",
    "dose_renal_function_normal": "250-1000 mg po q6h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h",
    "hemodialysis": "250-500 mg q12-24h (give AD on dialysis days)",
    "capd": "250-500 mg q12-24h",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Hypersensitivity (rash, urticaria, angioedema, anaphylaxis, erythema multiforme, serum sickness, SJS, TEN)",
    "Cephalexin has the same R-1 side chain as ampicillin and cefaclor, and the same R-2 side chain as cefadroxil.",
    "See Drug Allergy: Penicillins, Cephalosporins, Overview.",
    "GI (diarrhea, nausea, vomiting, abdominal pain, C. difficile colitis)",
    "Hematologic: positive Coombs, neutropenia, eosinophilia",
    "Reversible interstitial nephritis",
    "Increased LFTs",
    "Prolonged INR",
    "Seizures"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": ["Staphylococcus saprophyticus"],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Cap (250, 500, 750 mg), Tab (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)",
    "food_recommendation": "Cap/tab/susp ± food",
    "oral_absorption_percent": "90",
    "tmax_hr": "1",
    "peak_serum_conc_ug_ml": "18 (500 mg po, SD)",
    "peak_urine_conc_ug_ml": "2200 (500 mg po, SD)",
    "protein_binding_percent": "5-15",
    "volume_of_distribution_vd_l_kg_vf": "0.38 L/kg (V/F)",
    "avg_serum_half_life_hr": "1",
    "elimination": "Renal",
    "bile_penetration_percent": "216",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "29 (500 mg po, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["MATE1"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Metformin",
          "effect": "↑ metformin",
          "management": "Monitor, adjust dosage"
      },
      {
          "drug": "Probenecid",
          "effect": "↑ cephalexin",
          "management": "Monitor, adjust dosage"
      }
  ]
}
